Cost-effectiveness of alternative strategies for use of 13-valent pneumococcal conjugate vaccine (PCV13) in Canadian adults-Reference-Cited by-同舟云学术

Cost-effectiveness of alternative strategies for use of 13-valent pneumococcal conjugate vaccine (PCV13) in Canadian adults

Published:2018-05-09 Issue:5-6 Volume:109 Page:756-768
ISSN:0008-4263
Container-title:Canadian Journal of Public Health
language:en
Short-container-title:Can J Public Health

Author:

Atwood Mark,Beausoleil Linda,Breton Marie-Claude,Laferriere Craig,Sato Reiko,Weycker Derek

Publisher

Springer Science and Business Media LLC

Subject

Public Health, Environmental and Occupational Health,General Medicine

Link

http://link.springer.com/article/10.17269/s41997-018-0050-9/fulltext.html

Reference70 articles.

1. Alberta Health. Alberta immunization policy. 1995-2014. Available at http://www.health.alberta.ca/professionals/immunization-poli .

2. Andrews, N. J., Waight, P. A., George, R. C., et al. (2012). Impact and effectiveness of 23-valent pneumococcal polysaccharide vaccine against invasive pneumococcal disease in the elderly in England and Wales. Vaccine, 30, 6802–6808.

3. Blommaert, A., Bilcke, J., Willem, L., et al. (2016). The cost-effectiveness of pneumococcal vaccination in healthy adults over 50: an exploration of influential factors for Belgium. Vaccine, 34(18), 2016–2012.

4. Bonten M, Bolkenbaas M, Huijts S, et al. (2014). Community-acquired pneumonia immunization trial in adults─CAPiTA. 9th International Symposium on Pneumococci and Pneumococcal Diseases Poster, Hyderabad, India, March 9-13, 2014. Available at: http://isppd.meetingxpert.net/swf/poster_viewer.aspx .

5. Canadian Agency for Drugs and Technologies in Health. Guidelines for the economic evaluation of health technologies [3rd Edition], 2006. Ottawa, Can Underwrit.

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Recalibrated estimates of non-bacteremic and bacteremic pneumococcal community acquired pneumonia in hospitalized Canadian adults from 2010 to 2017 with addition of an extended spectrum serotype-specific urine antigen detection assay;Vaccine;2022-04

2. Cost-effectiveness analysis for PCV13 in adults 60 years and over with underlying medical conditions which put them at an elevated risk of pneumococcal disease in Japan;Expert Review of Vaccines;2021-07-30

3. Cost-Effectiveness Analysis of 23-Valent Pneumococcal Polysaccharide Vaccine Program for the Elderly Aged 60 Years or Older in Shanghai, China;Frontiers in Public Health;2021-05-24

4. Cost-effectiveness of low-dose colchicine after myocardial infarction in the Colchicine Cardiovascular Outcomes Trial (COLCOT);European Heart Journal - Quality of Care and Clinical Outcomes;2020-05-14

5. Health and Economic Impact of Routine Pediatric Pneumococcal Immunization Programs in Canada: A Retrospective Analysis;Infectious Diseases and Therapy;2020-04-08